Tazemetostat
Tazemetostat is a pharmaceutical drug with 50 clinical trials. Currently 17 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
28
Early Stage
18
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
14 of 28 finished
50.0%
14 ended early
17
trials recruiting
50
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
Clinical Trials (50)
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Study of Tazemetostat in Lymphoid Malignancies
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Tazemetostat and Palbociclib With CPX-351for R/R AML
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
Combining Epigenetic And Immune Therapy to Beat Cancer.
A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 50